NYSEAMERICAN:VNRX

VolitionRx Stock Forecast, Price & News

$3.15
+0.06 (+1.94 %)
(As of 07/29/2021 04:48 PM ET)
Add
Compare
Today's Range
$3.06
$3.20
50-Day Range
$2.88
$4.33
52-Week Range
$2.85
$6.67
Volume107,573 shs
Average Volume327,025 shs
Market Capitalization$166.61 million
P/E RatioN/A
Dividend YieldN/A
Beta1.76
30 days | 90 days | 365 days | Advanced Chart
Receive VNRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.


VolitionRx logo

About VolitionRx

VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on August 5, 2010 and is headquartered in Austin, TX.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.07 out of 5 stars

Medical Sector

198th out of 2,216 stocks

Diagnostic Substances Industry

2nd out of 38 stocks

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











VolitionRx (NYSEAMERICAN:VNRX) Frequently Asked Questions

Is VolitionRx a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VolitionRx stock.
View analyst ratings for VolitionRx
or view top-rated stocks.

What stocks does MarketBeat like better than VolitionRx?

Wall Street analysts have given VolitionRx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but VolitionRx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting VolitionRx?

VolitionRx saw a drop in short interest during the month of June. As of June 30th, there was short interest totaling 817,400 shares, a drop of 58.9% from the June 15th total of 1,990,000 shares. Based on an average trading volume of 234,400 shares, the short-interest ratio is presently 3.5 days. Currently, 2.4% of the company's stock are sold short.
View VolitionRx's Short Interest
.

When is VolitionRx's next earnings date?

VolitionRx is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for VolitionRx
.

How were VolitionRx's earnings last quarter?

VolitionRx Limited (NYSEAMERICAN:VNRX) announced its quarterly earnings results on Tuesday, May, 11th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.00. The medical research company earned $0.03 million during the quarter. VolitionRx had a negative net margin of 52,866.67% and a negative trailing twelve-month return on equity of 96.93%.
View VolitionRx's earnings history
.

What price target have analysts set for VNRX?

3 brokerages have issued 12-month price targets for VolitionRx's shares. Their forecasts range from $8.00 to $10.00. On average, they expect VolitionRx's share price to reach $8.67 in the next year. This suggests a possible upside of 175.1% from the stock's current price.
View analysts' price targets for VolitionRx
or view top-rated stocks among Wall Street analysts.

Who are VolitionRx's key executives?

VolitionRx's management team includes the following people:
  • Cameron John Reynolds, President, Chief Executive Officer & Director
  • Gaetan Michel, Chief Operating Officer
  • Terig Hughes, Chief Financial Officer & Treasurer
  • Jason Bradley Terrell, Chief Medical Officer & Head-US Operations
  • Jacob Vincent Micallef, Chief Scientific Officer

Who are some of VolitionRx's key competitors?

What other stocks do shareholders of VolitionRx own?

What is VolitionRx's stock symbol?

VolitionRx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."

How do I buy shares of VolitionRx?

Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VolitionRx's stock price today?

One share of VNRX stock can currently be purchased for approximately $3.15.

How much money does VolitionRx make?

VolitionRx has a market capitalization of $166.61 million and generates $10,000.00 in revenue each year. The medical research company earns $-20,350,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis.

How many employees does VolitionRx have?

VolitionRx employs 65 workers across the globe.

What is VolitionRx's official website?

The official website for VolitionRx is www.volitionrx.com.

Where are VolitionRx's headquarters?

VolitionRx is headquartered at 13215 BEE CAVE PARKWAY GALLERIA OAKS B SUITE 125, AUSTIN TX, 78738.

How can I contact VolitionRx?

VolitionRx's mailing address is 13215 BEE CAVE PARKWAY GALLERIA OAKS B SUITE 125, AUSTIN TX, 78738. The medical research company can be reached via phone at (646) 650-1351 or via email at [email protected]


This page was last updated on 7/30/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.